# VIKTORIA-1 (NCT05501886)

> Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05501886
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Celcuity Inc
- Conditions: Breast Cancer
- Interventions: Gedatolisib; Palbociclib; Fulvestrant; Alpelisib
- Enrollment: 701
- Primary outcome: Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer

## Commentary we found

- X threads: 96
- YouTube: 52
- Podcasts: 43
- X videos: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=viktoria-1-nct05501886

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05501886", "email": "<work email>"}; the inbox owner confirms by the emailed link.